Filing Flows › Teladoc Health (TDOC) › R&D spending
Teladoc Health (TDOC) R&D spending by quarter
Teladoc Health's R&D spending was $65.5M in Q3 2026 (third quarter 2026), +4% from Q2 2026. Over the last 7 quarters it ranged from $62.9M (Q2 2026) to $71.6M (Q4 2025).
| Quarter | R&D spending | Q/Q | Y/Y |
|---|---|---|---|
| Q3 2026 | $65.5M | +4% | -3% |
| Q2 2026 | $62.9M | -7% | -9% |
| Q1 2026 | $67.9M | -5% | -3% |
| Q4 2025 | $71.6M | +6% | — |
| Q3 2025 | $67.6M | -2% | — |
| Q2 2025 | $68.8M | -2% | — |
| Q1 2025 | $70.0M | — | — |
Q3 2026 at a glance
Teladoc Health, Q3 2026: revenue $605M (-3% year over year), operating margin -4.6%, net loss $26.9M, operating cash flow $106M. The chart follows the revenue to costs, profit and cash.
Questions
What is Teladoc Health's R&D spending?
Teladoc Health's R&D spending was $65.5M in Q3 2026 (third quarter 2026), +4% from Q2 2026.
How has Teladoc Health's R&D spending changed?
Over the last 7 quarters it ranged from $62.9M (Q2 2026) to $71.6M (Q4 2025).